Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why

Shares of Qualigen Therapeutics, Inc. (NASDAQ:QLGN) fell 5.2% on Thursday . The company traded as low as $4.15 and last traded at $4.17. 18,089 shares were traded during trading, a decline of 22% from the average session volume of 23,158 shares. The stock had previously closed at $4.40.

Qualigen Therapeutics Price Performance

The business has a fifty day simple moving average of $4.32 and a 200-day simple moving average of $7.84.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.